Drug Database · Clinicians

Amphotericin b

Brands (15) Amboter, Amboter C, Amfucin…Show all

Lipid-based Polyene Antifungal; Polyene Antifungal US FDA class
Antifungal (antibiotic); Antifungal / antimycotic; and others PH FDA category

Rx · Prescription drug15 PH productsPNF-listed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 02aadef1-390b-4270-b56d-33452eb89dde, version date April 20, 2026 (Amphotericin B · Sun Pharmaceutical Industries, Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS AND USAGE Amphotericin B liposome for injection is indicated for the following: Empirical therapy for presumed fungal infection in febrile, neutropenic patients.
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE Amphotericin B liposome for injection is indicated for the following: Empirical therapy for presumed fungal infection in febrile, neutropenic patients. Treatment of Cryptococcal Meningitis in HIV-infected patients (see DESCRIPTION OF CLINICAL STUDIES). Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate.

Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with amphotericin B liposome for injection, relapse rates were high following initial clearance of parasites (see DESCRIPTION OF CLINICAL STUDIES). See DOSAGE AND ADMINISTRATION for recommended doses by indication.

Contraindications

CONTRAINDICATIONS Amphotericin B liposome for injection is contraindicated in those patients who have demonstrated or have a known hypersensitivity to amphotericin B deoxycholate or any other constituents of the product unless, in the opinion of the treating physician, the benefit of therapy outweighs the risk.

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION Amphotericin B liposome for injection is not interchangeable or substitutable on a mg per mg basis with other amphotericin B products. Different amphotericin B products are not equivalent in terms of pharmacodynamics, pharmacokinetics and dosing. Amphotericin B liposome for injection should be administered by intravenous infusion, using a controlled infusion device, over a period of approximately 120 minutes.

An in-line membrane filter may be used for the intravenous infusion of amphotericin B liposome for injection, provided THE MEAN PORE DIAMETER OF THE FILTER IS NOT LESS THAN 1.0 MICRON. NOTE: An existing intravenous line must be flushed with 5% Dextrose Injection prior to infusion of amphotericin B liposome for injection.

If this is not feasible, amphotericin B liposome for injection must be administered through a separate line. Infusion time may be reduced to approximately 60 minutes in patients in whom the treatment is well-tolerated. If the patient experiences discomfort during infusion, the duration of infusion may be increased. The recommended initial dose of amphotericin B liposome for injection for each indication for adult and pediatric patients is as follows: Indication Dose (mg/kg/day) Empirical therapy 3 Systemic fungal infections: Aspergillus Candida Cryptococcus 3 to 5 Cryptococcal meningitis in HIV-infected patients (see DESCRIPTION OF CLINICAL STUDIES) 6 Dosing and rate of infusion should be individualized to the needs of the specific patient to ensure maximum efficacy while minimizing systemic toxicities or adverse events.

Doses recommended for visceral leishmaniasis are presented below: Visceral Leishmaniasis Dose (mg/kg/day) Immunocompetent patients 3 (days 1 to 5) and 3 on days 14, 21 Immunocompromised patients 4 (days 1 to 5) and 4 on days 10, 17, 24, 31, 38 For immunocompetent patients who do not achieve parasitic clearance with the recommended dose, a repeat course of therapy may be useful. For immunocompromised patients who do not clear parasites or who experience relapses, expert advice regarding further treatment is recommended.

For additional information, see DESCRIPTION OF CLINICAL STUDIES. Directions for Reconstitution, Filtration and Dilution Read This Entire Section Carefully Before Beginning Reconstitution Amphotericin B liposome for injection must be reconstituted using Sterile Water for Injection, USP (without a bacteriostatic agent). Vials of amphotericin B liposome for injection containing 50 mg of amphotericin B are prepared as follows: Reconstitution 1.

Aseptically add 12 mL of Sterile Water for Injection, USP to each amphotericin B liposome for injection vial to yield a preparation containing 4 mg amphotericin B/mL. CAUTION: DO NOT RECONSTITUTE WITH SALINE OR ADD SALINE TO THE RECONSTITUTED CONCENTRATION, OR MIX WITH OTHER DRUGS. The use of any solution other than those recommended, or the presence of a bacteriostatic agent in the solution, may cause precipitation of amphotericin B liposome for injection. 2.

Immediately after the addition of water, SHAKE THE VIAL VIGOROUSLY for 30 seconds to completely disperse the amphotericin B liposome for injection. Amphotericin B liposome for injection forms a yellow, translucent suspension. Visually inspect the vial for particulate matter and continue shaking until completely dispersed.

Filtration and Dilution 3. Calculate the amount of reconstituted (4 mg/mL) amphotericin B liposome for injection to be further diluted. 4. Withdraw this amount of reconstituted amphotericin B liposome for injection into a sterile syringe. 5. Attach the 5 micron filter provided to the syringe. Inject the syringe contents through the filter, into the appropriate amount of 5% Dextrose Injection (use only one filter per vial of amphotericin B liposome for injection). 6.

Amphotericin B liposome for injection must be diluted with 5% Dextrose Injection to a final concentration of 1 mg/mL to 2 mg/mL prior to administration. Lower concentrations (0.2 mg/mL to 0.5 mg/mL) may be appropriate for infants and small children to provide sufficient volume for infusion. DISCARD PARTIALLY USED VIALS. STORAGE OF AMPHOTERICIN B LIPOSOME FOR INJECTION Unopened vials of lyophilized material are to be stored at temperatures 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

Storage of Reconstituted Product Concentrate The reconstituted product concentrate may be stored for up to 24 hours at 2°C to 8°C (36°F to 46°F) following reconstitution with Sterile Water for Injection, USP. Do not freeze. Storage of Diluted Product Amphotericin B liposome for injection should commence within 6 hours of dilution with 5% Dextrose Injection.

As with all parenteral drug products, the reconstituted amphotericin B liposome for injection should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use material if there is any evidence of precipitation or foreign matter. Aseptic technique must be strictly observed in all handling, since no preservative or bacteriostatic agent is present in amphotericin B liposome for injection or in the materials specified for reconstitution and dilution.

Dosing: Altered kidney function

From the US FDA label · Renal impairment (clinical pharmacology)

Renal Impairment The effect of renal impairment on the disposition of amphotericin B after administration of amphotericin B liposome for injection has not been studied. However, amphotericin B liposome for injection has been successfully administered to patients with preexisting renal impairment (see DESCRIPTION OF CLINICAL STUDIES).

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

Pediatric Use Pediatric patients, age 1 month to 16 years, with presumed fungal infection (empirical therapy), confirmed systemic fungal infections or with visceral leishmaniasis have been successfully treated with amphotericin B liposome for injection. In studies which included 302 pediatric patients administered amphotericin B liposome for injection, there was no evidence of any differences in efficacy or safety of amphotericin B liposome for injection compared to adults.

Since pediatric patients have received amphotericin B liposome for injection at doses comparable to those used in adults on a per kilogram body weight basis, no dosage adjustment is required in this population. Safety and effectiveness in pediatric patients below the age of one month have not been established (See DESCRIPTION OF CLINICAL STUDIES - Empirical Therapy in Febrile Neutropenic Patients and DOSAGE AND ADMINISTRATION).

Dosing: Older adult

Geriatric use (US label) US FDA label

Elderly Patients Experience with amphotericin B liposome for injection in the elderly (65 years or older) comprised 72 patients. It has not been necessary to alter the dose of amphotericin B liposome for injection for this population. As with most other drugs, elderly patients receiving amphotericin B liposome for injection should be carefully monitored.

Dosage forms

Philippines

  • Lyophilized powder for injection: 50 mg
  • ) lipid complex suspension for injection: 5 mg/mL (50 mg/10 mL
  • ) suspension for injection: 5 mg/mL (50 mg/10 mL
  • Lyophilized powder for injection for i.v: 50 mg
  • Lyophilized powder for intravenous infusion: 50 mg
  • Lyophilized powder for iv infusion: 50 mg

Registered products in the Philippines

15 products registered with the Food and Drug Administration (FDA) Philippines list Amphotericin b as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products15
Philippine FDA-registered products for Amphotericin b
Package insert
AmboterAmphotericin B
50 mg Lyophilized Powder for Injection (IV)USP Type I clear and colorless glass vial with grey bromobutyl rubber stopper with sky blue-colored aluminum. flip-off seal (Box of 1's)
Rx
Aspiro Pharma LimitedIndia
Camber Pharmaceuticals, Inc.
DRP-17570
Feb 4, 2031
Amboter CAmphotericin B
50 mg Lyophilized Powder for Injection (IV)10 mL USP Type I Clear Glass Vial (Box of 1’s)
Rx
Lyka Labs LimitedIndia
Camber Pharmaceuticals, Inc.Importer: Ambica International Corporation
DRP-6931-02
Nov 25, 2031
AmfucinAmphotericin B
50 mg Lyophilized Powder for Injection (IV)USP Type I Transparent Glass Vial with Gray Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal x 10 mL (Box of 1's)
Rx
U Square Lifescience Pvt., Ltd.India
Endure Medical Inc.Importer: Skingen Biotech Inc.
DR-XY41725
Jun 17, 2031
AmphizoneAmphotericin B
50 mg Lyophilized Powder for Injection (IV)10 mL USP Type I Glass Vial with 200 mm grey bromobutyl rubber stopper and 20 mm royal blue aluminum flip off seal (Box of 1’s)
Rx
Gufic Biosciences LimitedIndia
Ambica International CorporationTrader: Gufic Striden Biopharma Pvt. Ltd.
DRP-10786
Nov 19, 2031
AmpholipAmphotericin B
5 mg/mL (50 mg/10 mL) Lipid Complex Suspension for Injection (IV)USP Type I Borosilicate Glass x 10 mL with filter needle (Box of 1's)
Rx
Bharat Serums and Vaccines LimitedIndia
BSV Bioscience Phils. Inc.
DR-XY35140
Nov 11, 2030
AmpholynAmphotericin B
50 mg Lyophilized Powder for Injection (I.V.)USP Type 1 clear glass vial with grey bromo butyl slotted rubber stopper and aluminum snap off seal with plastic cover (Box of 1's)
Rx
Lyka Labs LimitedIndia
Blue Global (FZE)
DRP-15664
Aug 16, 2029
AmphonexAmphotericin B
50 mg Lyophilized Powder for Intravenous Infusion20 mL USP Type I clear colorless tubular vial with 20 mm chlorobutyl slotted rubber bung and 20 mm royal blue aluminum flip off seal with 5 micron syringe filter (Box of 1’s)
Rx
Bharat Serums and Vaccines LimitedIndia
BSV Bioscience Phils. Inc.
DR-XY47267
May 11, 2031
AmphostalAmphotericin B
50 mg Lyophilized Powder for IV InfusionIn a box of 1 USP Type I Flint Glass Vial x 10 mL
Rx
Gufic Biosciences LimitedIndia
Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-5890
Dec 17, 2029
AmphotAmphotericin B
50 mg Lyophilized Powder for Injection (IV)10 mL USP Type I Clear Glass Vial (Box of 1's)
Rx
Lyka Labs LimitedIndia
Ambica International Corporation
DRP-6931
Nov 25, 2031
AmphotretAmphotericin B
50 mg Lyophilized Powder for Injection (IV)USP Type I Glass Vial with Rubber Stopper and Green Flip Top Seal (Box of 1's)
Rx
Bharat Serums and Vaccines LimitedIndia
Sandoval Distributors, Inc.Importer: BSV Bioscience Phils. Inc.
DR-XY33551
Jul 6, 2029
Ampothin-Lip 50Amphotericin B
5 mg/mL (50 mg/10 mL) Suspension for Injection (I.V.)10 mL Type I Clear moulded Glass vial stoppered and sealed with 20 mm grey butyl rubber stopper and 20 mm blue color flip off seal having embossed "United Biotech" (Box of 1's)
Rx
United Biotech (P) Limited.India
Bliss Pharma Distribution and Consultancy Corp
DRP-15529
Aug 1, 2029
AmpriwestAmphotericin B
50 mg Lyophilized Powder for Injection (IV)Type I Vial x 10 mL (Box of 1's)
Rx
Lyka Labs LimitedIndia
Central West Medicale Inc.Importer: Ambica International Corporation
DRP-6931-01
Oct 17, 2031
Impho-BAmphotericin B
50 mg Lyophilized Powder for Injection (I.V.)USP Type I Glass Vial x 10 mL (Box of 1's)
Rx
Gufic Biosciences Ltd.India
SRS Life Sciences Inc.
DRP-5150
Jan 27, 2027
Liphoject-BAmphotericin B
50 mg Lyophilized Powder For Injection (Iv)USP Type I clear glass vial x 25 mL (net content) with grey bromobutyl rubber stopper and aluminum seal and flip-off cap + 5μm sterile syringe filter (Box of 1's)
Rx
Jodas Expoim Private LimitedIndia
One Dexcel Pharma, Inc.
DR-XY49748
Jun 17, 2031
LipholynAmphotericin-B
50 mg Lyophilized Powder For Injection For I.V20 mL Type I Clear Transparent Glass Vial with Gray Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal Cap x 1's (Box of 1's)
Rx
Lyka Labs LimitedIndia
Ambica International Corporation
DRP-14156
Jul 3, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

WARNINGS Anaphylaxis has been reported with amphotericin B deoxycholate and other amphotericin B-containing drugs, including amphotericin B liposome for injection. If a severe anaphylactic reaction occurs, the infusion should be immediately discontinued and the patient should not receive further infusions of amphotericin B liposome for injection.

Drug interactions

Drug interactions (US label) US FDA label

Drug Interactions No formal clinical studies of drug interactions have been conducted with amphotericin B liposome for injection; however, the following drugs are known to interact with amphotericin B and may interact with amphotericin B liposome for injection: Antineoplastic Agents Concurrent use of antineoplastic agents may enhance the potential for renal toxicity, bronchospasm, and hypotension. Antineoplastic agents should be given concomitantly with caution.

Corticosteroids and Corticotropin (ACTH) Concurrent use of corticosteroids and ACTH may potentiate hypokalemia, which could predispose the patient to cardiac dysfunction. If used concomitantly, serum electrolytes and cardiac function should be closely monitored. Digitalis Glycosides Concurrent use may induce hypokalemia and may potentiate digitalis toxicity.

When administered concomitantly, serum potassium levels should be closely monitored. Flucytosine Concurrent use of flucytosine may increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion. Azoles (e.g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.) In vitro and in vivo animal studies of the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.

Combination therapy should be administered with caution, especially in immunocompromised patients. Leukocyte Transfusions Acute pulmonary toxicity has been reported in patients simultaneously receiving intravenous amphotericin B and leukocyte transfusions. Other Nephrotoxic Medications Concurrent use of amphotericin B and other nephrotoxic medications may enhance the potential for drug-induced renal toxicity.

Intensive monitoring of renal function is recommended in patients requiring any combination of nephrotoxic medications. Skeletal Muscle Relaxants Amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g. tubocurarine) due to hypokalemia. When administered concomitantly, serum potassium levels should be closely monitored.

Adverse reactions

Adverse reactions (US label) US FDA label

ADVERSE REACTIONS The following adverse events are based on the experience of 592 adult patients (295 treated with amphotericin B liposome for injection and 297 treated with amphotericin B deoxycholate) and 95 pediatric patients (48 treated with amphotericin B liposome for injection and 47 treated with amphotericin B deoxycholate) in Study 94-0-002, a randomized double-blind, multicenter study in febrile, neutropenic patients. Amphotericin B liposome for injection and amphotericin B were infused over two hours.

The incidence of common adverse events (incidence of 10% or greater) occurring with amphotericin B liposome for injection compared to amphotericin B deoxycholate, regardless of relationship to study drug, is shown in the following table: Empirical Therapy Study 94-0-002 Common Adverse Events Adverse Event by Body System Amphotericin B Liposome for Injection N=343 % Amphotericin B N=344 % Body as a Whole Abdominal pain 19.8 21.8 Asthenia 13.1 10.8 Back pain 12 7.3 Blood product transfusion reaction 18.4 18.6 Chills 47.5 75.9 Infection 11.1 9.3 Pain 14 12.8 Sepsis 14 11.3 Cardiovascular System Chest pain 12 11.6 Hypertension 7.9 16.3 Hypotension 14.3 21.5 Tachycardia 13.4 20.9 Digestive System Diarrhea 30.3 27.3 Gastrointestinal hemorrhage 9.9 11.3 Nausea 39.7 38.7 Vomiting 31.8 43.9 Metabolic and Nutritional Disorders Alkaline phosphatase increased 22.2 19.2 ALT (SGPT) …

6.4 Hypertension 10

6.4 Hypertension 10.6 19.8 23.1 Hypotension 10.6 7.4 19.2 Tachycardia 9.4 18.5 23.1 Digestive System Diarrhea 15.3 17.3 14.1 Nausea 25.9 29.6 37.2 Vomiting 22.4 25.9 30.8 Metabolic and Nutritional Disorders Alkaline phosphatase increased 7.1 8.6 12.8 Bilirubinemia 16.5 11.1 11.5 BUN increased 20 18.5 28.2 Creatinine increased 20 18.5 48.7 Edema 12.9 12.3 12.8 Hyperglycemia 8.2 8.6 14.1 Hypervolemia 8.2 11.1 14.1 Hypocalcemia 10.6 4.9 5.1 Hypokalemia 37.6 43.2 39.7 Hypomagnesemia 15.3 25.9 15.4 Liver function tests abnormal 10.6 7.4 11.5 Nervous System Anxiety 10.6 7.4 9 Confusion 12.9 8.6 3.8 Headache 9.4 17.3 10.3 Respiratory System Dyspnea 17.6 22.2 23.1 Epistaxis 10.6 8.6 14.1 Hypoxia 7.1 6.2 20.5 Lung disorder 14.1 13.6 15.4 Skin and Appendages Rash 23.5 22.2 14.1 The following adverse events are based on the experience of 267 patients (266 adult patients and 1 pediatric patient) of whom 86 patients were treated with amphotericin B liposome for injection 3 mg/kg, 94 patients were treated with amphotericin B liposome for injection 6 mg/kg and 87 patients were treated with amphotericin B deoxycholate 0.7 mg/kg in Study 94-0-013 a randomized, double-blind, comparative multicenter trial, in the treatment of cryptococcal meningitis in HIV-positive patients. The incidence of adverse events occurring in more than 10% of subjects in one or more arms regardless of relationship to study drug are summarized in the following table: Cryptococcal Meningitis Therapy Study 94-0-013 Common Adverse Events Adverse Event by Body System Amphotericin B Liposome for Injection 3 mg/kg/day N=86 % Amphotericin B Liposome for Injection 6 mg/kg/day N=94 % Amphotericin B 0.7 mg/kg/day N=87 % Body as a Whole Abdominal pain 7 7.4 10.3 Infection 12.8 11.7

6.9 Procedural Complication 8

6.9 Procedural Complication 8.1 9.6 10.3 Cardiovascular System Phlebitis 9.3 10.6 25.3 Digestive System Anorexia 14 9.6 11.5 Constipation 15.1 14.9 20.7 Diarrhea 10.5 16 10.3 Nausea 16.3 21.3 25.3 Vomiting 10.5 21.3 20.7 Hemic and Lymphatic System Anemia 26.7 47.9 43.7 Leukopenia 15.1 17 17.2 Thrombocytopenia 5.8 12.8

6.9 Metabolic and Nutritional Disorders Bilirubinemia 0 8

6.9 Metabolic and Nutritional Disorders Bilirubinemia 0 8.5 12.6 BUN increased 9.3 7.4 10.3 Creatinine increased 18.6 39.4 43.7 Hyperglycemia 9.3 12.8 17.2 Hypocalcemia 12.8 17 13.8 Hypokalemia 31.4 51.1 48.3 Hypomagnesemia 29.1 48.9 40.2 Hyponatremia 11.6 8.5 9.2 Liver Function Tests Abnormal 12.8 4.3 9.2 Nervous System Dizziness 7 8.5 10.3 Insomnia 22.1 17 20.7 Respiratory System Cough Increased 8.1 2.1 10.3 Skin and Appendages Rash 4.7 11.7 4.6 Infusion-Related Reactions In Study 94-0-002, the large, double-blind study of pediatric and adult febrile neutropenic patients, no premedication to prevent infusion-related reaction was administered prior to the first dose of study drug (Day 1). Amphotericin B liposome for injection-treated patients had a lower incidence of infusion-related fever (17% versus 44%), chills/rigors (18% versus 54%) and vomiting (6% versus 8%) on Day 1 as compared to amphotericin B deoxycholate-treated patients.

The incidence of infusion-related reactions on Day 1 in pediatric and adult patients is summarized in the following table: Incidence of Day 1 Infusion-Related Reactions (IRR) By Patient Age Pediatric Patients (≤ 16 years of age) Adult Patients (>16 years of age) Amphotericin B Liposome for Injection 3 mg/kg/day Amphotericin B 0.6 mg/kg/day Amphotericin B Liposome for Injection 3 mg/kg/day Amphotericin B 0.6 mg/kg/day Total number of patients receiving at least one dose of study drug 48 47 295 297 Patients with fever† Increase ≥1.0ºC 6 (13%) 22 (47%) 52 (18%) 128 (43%) Patients with chills/rigors 4 (8%) 22 (47%) 59 (20%) 165 (56%) Patients with nausea 4 (8%) 4 (9%) 38 (13%) 31 (10%) Patients with vomiting 2 (4%) 7 (15%) 19 (6%) 21 (7%) Patients with other reactions 10 (21%) 13 (28%) 47 (16%) 69 (23%) †Day 1 body temperature increased above the temperature taken within 1 hour prior to infusion (preinfusion temperature) or above the lowest infusion value (no preinfusion temperature recorded). Cardiorespiratory events, except for vasodilatation (flushing), during all study drug infusions were more frequent in amphotericin B-treated patients as summarized in the following table: Incidence of Infusion-Related Cardiorespiratory Events Event Amphotericin B Liposome for Injection 3 mg/kg/day N=343 Amphotericin B 0.6 mg/kg/day N=344 Hypotension 12 (3.5%) 28 (8.1%) Tachycardia 8 (2.3%) 43 (12.5%) Hypertension 8 (2.3%) 39 (11.3%) Vasodilatation 18 (5.2%) 2 (0.6%) Dyspnea 16 (4.7%) 25 (7.3%) Hyperventilation 4 (1.2%) 17 (4.9%) Hypoxia 1 (0.3%) 22 (6.4%) The percentage of patients who received drugs either for the treatment or prevention of infusion-related reactions (e.g., acetaminophen, diphenhydramine, meperidine and hydrocortisone) was lower in amphotericin B liposome for injection-treated patients compared with amphotericin B deoxycholate-treated patients.

In the empirical therapy study 97-0-034, on Day 1, where no premedication was administered, the overall incidence of infusion-related events of chills/rigors was significantly lower for patients administered amphotericin B liposome for injection compared with amphotericin B lipid complex. Fever, chills/rigors and hypoxia were significantly lower for each amphotericin B liposome for injection group compared with the amphotericin B lipid complex group.

The infusion-related event hypoxia was reported for 11.5% of amphotericin B lipid complex-treated patients compared with 0% of patients administered 3 mg/kg per day amphotericin B liposome for injection and 1.2% of patients treated with 5 mg/kg per day amphotericin B liposome for injection. Incidence of Day 1 Infusion-Related Reactions (IRR) Chills/Rigors Empirical Therapy Study 97-0-034 Amphotericin B Liposome for Injection Amphotericin B lipid complex 5 mg/kg/day 3 mg/kg/day 5 mg/kg/day BOTH Total number of patients 85 81 166 78 Patients with Chills/Rigors (Day 1) 16 (18.8%) 19 (23.5%) 35 (21.1%) 62 (79.5%) Patients with other notable reactions: Fever (>1.0ºC increase in temperature) 20 (23.5%) 16 (19.8%) 36 (21.7%) 45 (57.7%) Nausea 9 (10.6%) 7 (8.6%) 16 (9.6%) 9 (11.5%) Vomiting 5 (5.9%) 5 (6.2%) 10 (6%) 11 (14.1%) Hypertension 4 (4.7%) 7 (8.6%) 11 (6.6%) 12 (15.4%) Tachycardia 2 (2.4%) 8 (9.9%) 10 (6%) 14 (17.9%) Dyspnea 4 (4.7%) 8 (9.9%) 12 (7.2%) 8 (10.3%) Hypoxia 0 1 (1.2%) 1 (<1%) 9 (11.5%) Day 1 body temperature increased above the temperature taken within 1 hour prior to infusion (preinfusion temperature) or above the lowest infusion value (no preinfusion temperature recorded).

Patients were not administered premedications to prevent infusion-related reactions prior to the Day 1 study drug infusion. In Study 94-0-013, a randomized, double-blind multicenter trial comparing amphotericin B liposome for injection and amphotericin B deoxycholate as initial therapy for cryptococcal meningitis, premedications to prevent infusion-related reactions were permitted.

Amphotericin B liposome for injection-treated patients had a lower incidence of fever, chill/rigors and respiratory adverse events as summarized in the following table: Incidence of Infusion-Related Reactions Study 94-0-013 Amphotericin B Liposome for Injection 3 mg/kg/day Amphotericin B Liposome for Injection 6 mg/kg/day Amphotericin B 0.7 mg/kg/day Total number of patients receiving at least one dose of study drug 86 94 87 Patients with fever increase of >1ºC 6 (7%) 8 (9%) 24 (28%) Patients with chills/rigors 5 (6%) 8 (9%) 42 (48%) Patients with nausea 11 (13%) 13 (14%) 18 (20%) Patients with vomiting 14 (16%) 13 (14%) 16 (18%) Respiratory adverse events 0 1 (1%) 8 (9%) There have been a few reports of flushing, back pain with or without chest tightness, and chest pain associated with amphotericin B liposome for injection administration; on occasion this has been severe. Where these symptoms were noted, the reaction developed within a few minutes after the start of infusion and disappeared rapidly when the infusion was stopped.

The symptoms do not occur with every dose and usually do not recur on subsequent administrations when the infusion rate is slowed. Toxicity and Discontinuation of Dosing In Study 94-0-002, a significantly lower incidence of grade 3 or 4 toxicity was observed in the amphotericin B liposome for injection group compared with the amphotericin B group.

In addition, nearly three times as many patients administered amphotericin B required a reduction in dose due to toxicity or discontinuation of study drug due to an infusion-related reaction compared with those administered amphotericin B liposome for injection. In empirical therapy study 97-0-034, a greater proportion of patients in the amphotericin B lipid complex group discontinued the study drug due to an adverse event than in the amphotericin B liposome for injection groups.

Less Common Adverse Events The following adverse events also have been reported in 2% to 10% of amphotericin B liposome for injection-treated patients receiving chemotherapy or bone marrow transplantation, or who had HIV disease in six comparative, clinical trials: Body as a Whole Abdomen enlarged, allergic reaction, cellulitis, cell-mediated immunological reaction, face edema, graft-versus-host disease, malaise, neck pain, and procedural complication. Cardiovascular System Arrhythmia, atrial fibrillation, bradycardia, cardiac arrest, cardiomegaly, hemorrhage, postural hypotension, valvular heart disease, vascular disorder, and vasodilatation (flushing).

Digestive System Anorexia, constipation, dry mouth/nose, dyspepsia, dysphagia, eructation, fecal incontinence, flatulence, hemorrhoids, gum/oral hemorrhage, hematemesis, hepatocellular damage, hepatomegaly, liver function test abnormal, ileus, mucositis, rectal disorder, stomatitis, ulcerative stomatitis, and veno-occlusive liver disease. Hemic & Lymphatic System Anemia, coagulation disorder, ecchymosis, fluid overload, petechia, prothrombin decreased, prothrombin increased, and thrombocytopenia.

Metabolic & Nutritional Disorders Acidosis, amylase increased, hyperchloremia, hyperkalemia, hypermagnesemia, hyperphosphatemia, hyponatremia, hypophosphatemia, hypoproteinemia, lactate dehydrogenase increased, nonprotein nitrogen (NPN) increased, and respiratory alkalosis. Musculoskeletal System Arthralgia, bone pain, dystonia, myalgia, and rigors.

Nervous System Agitation, coma, convulsion, cough, depression, dysesthesia, dizziness, hallucinations, nervousness, paresthesia, somnolence, thinking abnormality, and tremor. Respiratory System Asthma, atelectasis, hemoptysis, hiccup, hyperventilation, influenza-like symptoms, lung edema, pharyngitis, pneumonia, respiratory insufficiency, respiratory failure, and sinusitis.

Skin & Appendages Alopecia, dry skin, herpes simplex, injection site inflammation, maculopapular rash, purpura, skin discoloration, skin disorder, skin ulcer, urticaria, and vesiculobullous rash. Special Senses Conjunctivitis, dry eyes, and eye hemorrhage. Urogenital System Abnormal renal function, acute kidney failure, acute renal failure, dysuria, kidney failure, toxic nephropathy, urinary incontinence, and vaginal hemorrhage.

Postmarketing Experience The following infrequent adverse experiences have been reported in postmarketing surveillance, in addition to those mentioned above: angioedema, erythema, urticaria, bronchospasm, cyanosis/hypoventilation, pulmonary edema, agranulocytosis, hemorrhagic cystitis, and rhabdomyolysis. Clinical Laboratory Values The effect of amphotericin B liposome for injection on renal and hepatic function and on serum electrolytes was assessed from laboratory values measured repeatedly in Study 94-0-002.

The frequency and magnitude of hepatic test abnormalities were similar in the amphotericin B liposome for injection and amphotericin B groups. Nephrotoxicity was defined as creatinine values increasing 100% or more over pretreatment levels in pediatric patients, and creatinine values increasing 100% or more over pretreatment levels in adult patients, provided the peak creatinine concentration was >1.2 mg/dL.

Hypokalemia was defined as potassium levels ≤2.5 mmol/L any time during treatment. Incidence of nephrotoxicity, mean peak serum creatinine concentration, mean change from baseline in serum creatinine, and incidence of hypokalemia in the double-blind, randomized study were lower in the amphotericin B liposome for injection group as summarized in the following table: Study 94-0-002 Laboratory Evidence of Nephrotoxicity Amphotericin B Liposome for Injection 3 mg/kg/day Amphotericin B 0.6 mg/kg/day Total number of patients receiving at least one dose of study drug 343 344 Nephrotoxicity 64 (18.7%) 116 (33.7%) Mean peak creatinine 1.24 mg/dL 1.52 mg/dL Mean change from baseline in creatinine 0.48 mg/dL 0.77 mg/dL Hypokalemia 23 (6.7%) 40 (11.6%) The effect of amphotericin B liposome for injection (3 mg/kg/day) vs. amphotericin B (0.6 mg/kg/day) on renal function in adult patients enrolled in this study is illustrated in the following figure: Mean Change in Creatinine Over Time in Study 94-0-002 In empirical therapy study 97-0-034, the incidence of nephrotoxicity as measured by increases of serum creatinine from baseline was significantly lower for patients administered amphotericin B liposome for injection (individual dose groups and combined) compared with amphotericin B lipid complex.

Incidence of Nephrotoxicity Empirical Therapy Study 97-0-034 Amphotericin B Liposome for Injection Amphotericin B lipid complex 5 mg/kg/day 3 mg/kg/day 5 mg/kg/day BOTH Total number of patients 85 81 166 78 Number with nephrotoxicity 1.5X baseline serum creatinine value 25 (29.4%) 21 (25.9%) 46 (27.7%) 49 (62.8%) 2X baseline serum creatinine value 12 (14.1%) 12 (14.8%) 24 (14.5%) 33 (42.3%) The following graph shows the average serum creatinine concentrations in the compassionate use study and shows that there is a drop from pretreatment concentrations for all patients, especially those with elevated (greater than 1.7 mg/dL) pretreatment creatinine concentrations. Mean Creatinine Concentrations Over Time The incidence of nephrotoxicity in Study 94-0-013 comparative trial in cryptococcal meningitis was lower in the amphotericin B liposome for injection groups as shown in the following table: Laboratory Evidence of Nephrotoxicity Study 94-0-013 Amphotericin B Liposome for Injection 3 mg/kg/day Amphotericin B Liposome for Injection 6 mg/kg/day Amphotericin B 0.7 mg/kg/day Total number of patients receiving at least one dose of study drug 86 94 87 Number with Nephrotoxicity (%) 1.5X baseline serum creatinine 30 (35%) 44 (47%) 52 (60%) 2 X baseline serum creatinine 12 (14%) 20 (21%) 29 (33%) spl-figure1 spl-figure2

Adverse reaction frequency tables (US label) US FDA label
Adverse Event by Body SystemAmphotericin B Liposome for Injection N=343 %Amphotericin B N=344 %
Body as a Whole
Abdominal pain19.821.8
Asthenia13.110.8
Back pain127.3
Blood product transfusion reaction18.418.6
Chills47.575.9
Infection11.19.3
Pain1412.8
Sepsis1411.3
Cardiovascular System
Chest pain1211.6
Hypertension7.916.3
Hypotension14.321.5
Tachycardia13.420.9
Digestive System
Diarrhea30.327.3
Gastrointestinal hemorrhage9.911.3
Nausea39.738.7
Vomiting31.843.9
Metabolic and Nutritional Disorders
Alkaline phosphatase increased22.219.2
ALT (SGPT) increased14.614
AST (SGOT) increased12.812.8
Bilirubinemia18.119.2
BUN increased2131.1
Creatinine increased22.442.2
Edema14.314.8
Hyperglycemia2327.9
Hypernatremia4.111
Hypervolemia12.215.4
Hypocalcemia18.420.9
Hypokalemia42.950.6
Hypomagnesemia20.425.6
Peripheral edema14.617.2
Nervous System
Anxiety13.711
Confusion11.413.4
Headache19.820.9
Insomnia17.214.2
Respiratory System
Cough increased17.821.8
Dyspnea2329.1
Epistaxis14.920.1
Hypoxia7.614.8
Lung disorder17.817.4
Pleural effusion12.59.6
Rhinitis11.111
Skin and Appendages
Pruritus10.810.2
Rash24.824.4
Sweating710.8
Urogenital System
Hematuria1414
Adverse Event by Body SystemAmphotericin B Liposome for Injection 3 mg/kg/day N=85 %Amphotericin B Liposome for Injection 5 mg/kg/day N=81 %Amphotericin B Lipid Complex 5 mg/kg/day N=78 %
Body as a Whole
Abdominal pain12.99.911.5
Asthenia8.26.211.5
Chills/rigors4048.189.7
Sepsis12.97.411.5
Transfusion reaction10.68.65.1
Cardiovascular System
Chest pain8.211.16.4
Hypertension10.619.823.1
Hypotension10.67.419.2
Tachycardia9.418.523.1
Digestive System
Diarrhea15.317.314.1
Nausea 25.929.637.2
Vomiting22.425.930.8
Metabolic and Nutritional Disorders
Alkaline phosphatase increased7.18.612.8
Bilirubinemia16.511.111.5
BUN increased2018.528.2
Creatinine increased2018.548.7
Edema12.912.312.8
Hyperglycemia8.28.614.1
Hypervolemia8.211.114.1
Hypocalcemia10.64.95.1
Hypokalemia37.643.239.7
Hypomagnesemia15.325.915.4
Liver function tests abnormal10.67.411.5
Nervous System
Anxiety10.67.49
Confusion12.98.63.8
Headache9.417.310.3
Respiratory System
Dyspnea17.622.223.1
Epistaxis10.68.614.1
Hypoxia7.16.220.5
Lung disorder14.113.615.4
Skin and Appendages
Rash23.522.214.1
Adverse Event by Body SystemAmphotericin B Liposome for Injection 3 mg/kg/day N=86 %Amphotericin B Liposome for Injection 6 mg/kg/day N=94 %Amphotericin B 0.7 mg/kg/day N=87 %
Body as a Whole
Abdominal pain77.410.3
Infection12.811.76.9
Procedural Complication8.19.610.3
Cardiovascular System
Phlebitis9.310.625.3
Digestive System
Anorexia149.611.5
Constipation15.114.920.7
Diarrhea10.51610.3
Nausea16.321.325.3
Vomiting10.521.320.7
Hemic and Lymphatic System
Anemia26.747.943.7
Leukopenia15.11717.2
Thrombocytopenia5.812.86.9
Metabolic and Nutritional Disorders
Bilirubinemia08.512.6
BUN increased9.37.410.3
Creatinine increased18.639.443.7
Hyperglycemia9.312.817.2
Hypocalcemia12.81713.8
Hypokalemia31.451.148.3
Hypomagnesemia29.148.940.2
Hyponatremia11.68.59.2
Liver Function Tests Abnormal12.84.39.2
Nervous System
Dizziness78.510.3
Insomnia22.11720.7
Respiratory System
Cough Increased8.12.110.3
Skin and Appendages
Rash4.711.74.6
Pediatric Patients (≤ 16 years of age)Adult Patients (>16 years of age)
Amphotericin B Liposome for Injection 3 mg/kg/dayAmphotericin B 0.6 mg/kg/dayAmphotericin B Liposome for Injection 3 mg/kg/dayAmphotericin B 0.6 mg/kg/day
Total number of patients receiving at least one dose of study drug4847295297
Patients with fever† Increase ≥1.0ºC6 (13%)22 (47%)52 (18%)128 (43%)
Patients with chills/rigors4 (8%)22 (47%)59 (20%)165 (56%)
Patients with nausea4 (8%)4 (9%)38 (13%)31 (10%)
Patients with vomiting2 (4%)7 (15%)19 (6%)21 (7%)
Patients with other reactions10 (21%)13 (28%)47 (16%)69 (23%)
EventAmphotericin B Liposome for Injection 3 mg/kg/day N=343Amphotericin B 0.6 mg/kg/day N=344
Hypotension12 (3.5%)28 (8.1%)
Tachycardia8 (2.3%)43 (12.5%)
Hypertension8 (2.3%)39 (11.3%)
Vasodilatation18 (5.2%)2 (0.6%)
Dyspnea16 (4.7%)25 (7.3%)
Hyperventilation4 (1.2%)17 (4.9%)
Hypoxia1 (0.3%)22 (6.4%)
Amphotericin B Liposome for InjectionAmphotericin B lipid complex 5 mg/kg/day
3 mg/kg/day5 mg/kg/dayBOTH
Total number of patients858116678
Patients with Chills/Rigors (Day 1)16 (18.8%)19 (23.5%)35 (21.1%)62 (79.5%)
Patients with other notable reactions: Fever (>1.0ºC increase in temperature)20 (23.5%)16 (19.8%)36 (21.7%)45 (57.7%)
Nausea9 (10.6%)7 (8.6%)16 (9.6%)9 (11.5%)
Vomiting5 (5.9%)5 (6.2%)10 (6%)11 (14.1%)
Hypertension4 (4.7%)7 (8.6%)11 (6.6%)12 (15.4%)
Tachycardia2 (2.4%)8 (9.9%)10 (6%)14 (17.9%)
Dyspnea4 (4.7%)8 (9.9%)12 (7.2%)8 (10.3%)
Hypoxia01 (1.2%)1 (<1%)9 (11.5%)
Incidence of Infusion-Related Reactions Study 94-0-013
Amphotericin B Liposome for Injection 3 mg/kg/dayAmphotericin B Liposome for Injection 6 mg/kg/dayAmphotericin B 0.7 mg/kg/day
Total number of patients receiving at least one dose of study drug869487
Patients with fever increase of >1ºC6 (7%)8 (9%)24 (28%)
Patients with chills/rigors5 (6%)8 (9%)42 (48%)
Patients with nausea11 (13%)13 (14%)18 (20%)
Patients with vomiting14 (16%)13 (14%)16 (18%)
Respiratory adverse events01 (1%)8 (9%)
Amphotericin B Liposome for Injection 3 mg/kg/dayAmphotericin B 0.6 mg/kg/day
Total number of patients receiving at least one dose of study drug343344
Nephrotoxicity64 (18.7%)116 (33.7%)
Mean peak creatinine1.24 mg/dL1.52 mg/dL
Mean change from baseline in creatinine0.48 mg/dL0.77 mg/dL
Hypokalemia23 (6.7%)40 (11.6%)
Amphotericin B Liposome for InjectionAmphotericin B lipid complex 5 mg/kg/day
3 mg/kg/day5 mg/kg/dayBOTH
Total number of patients858116678
Number with nephrotoxicity
1.5X baseline serum creatinine value25 (29.4%)21 (25.9%)46 (27.7%)49 (62.8%)
2X baseline serum creatinine value12 (14.1%)12 (14.8%)24 (14.5%)33 (42.3%)
Laboratory Evidence of Nephrotoxicity Study 94-0-013
Amphotericin B Liposome for Injection 3 mg/kg/dayAmphotericin B Liposome for Injection 6 mg/kg/dayAmphotericin B 0.7 mg/kg/day
Total number of patients receiving at least one dose of study drug869487
Number with Nephrotoxicity (%)
1.5X baseline serum creatinine30 (35%)44 (47%)52 (60%)
2 X baseline serum creatinine12 (14%)20 (21%)29 (33%)

Pregnancy considerations

Pregnancy (US label) US FDA label

Pregnancy There have been no adequate and well-controlled studies of amphotericin B liposome for injection in pregnant women. Systemic fungal infections have been successfully treated in pregnant women with amphotericin B deoxycholate, but the number of cases reported has been small. Segment II studies in both rats and rabbits have concluded that amphotericin B liposome for injection had no teratogenic potential in these species.

In rats, the maternal non-toxic dose of amphotericin B liposome for injection was estimated to be 5 mg/kg (equivalent to 0.16 to 0.8 times the recommended human clinical dose range of 1 mg/kg to 5 mg/kg) and in rabbits, 3 mg/kg (equivalent to 0.2 to 1 times the recommended human clinical dose range), based on body surface area correction. Rabbits receiving the higher doses, (equivalent to 0.5 to 2 times the recommended human dose) of amphotericin B liposome for injection experienced a higher rate of spontaneous abortions than did the control groups.

Amphotericin B liposome for injection should only be used during pregnancy if the possible benefits to be derived outweigh the potential risks involved.

Breastfeeding considerations

Lactation (US label) US FDA label

Nursing Mothers Many drugs are excreted in human milk; however, it is not known whether amphotericin B is excreted in human milk. Due to the potential for serious adverse reactions in breastfed infants, a decision should be made whether to discontinue nursing or whether to discontinue the drug, taking into account the importance of the drug to the mother.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

However, based on total amphotericin B concentration measured up to 49 days after dosing of amphotericin B liposome for injection, the mean half-life was 100 to 153 hours.

The long terminal elimination half-life is probably a slow redistribution from tissues.

Excretion The mean clearance at steady state was independent of dose.

The excretion of amphotericin B after administration of amphotericin B liposome for injection has not been studied.

Pharmacokinetics (US label) US FDA label

CLINICAL PHARMACOLOGY Pharmacokinetics The assay used to measure amphotericin B in the serum after administration of amphotericin B liposome for injection does not distinguish amphotericin B that is complexed with the phospholipids of amphotericin B liposome for injection from amphotericin B that is uncomplexed. The pharmacokinetic profile of amphotericin B after administration of amphotericin B liposome for injection is based upon total serum concentrations of amphotericin B.

The pharmacokinetic profile of amphotericin B was determined in febrile neutropenic cancer and bone marrow transplant patients who received 1 to 2 hour infusions of 1 mg/kg/day to 5 mg/kg/day amphotericin B liposome for injection for 3 to 20 days. The pharmacokinetics of amphotericin B after administration of amphotericin B liposome for injection is nonlinear such that there is a greater than proportional increase in serum concentrations with an increase in dose from 1 mg/kg/day to 5 mg/kg/day.

The pharmacokinetic parameters of total amphotericin B (mean ± SD) after the first dose and at steady state are shown in the table below. Pharmacokinetic Parameters of Amphotericin B Liposome for Injection Dose 1 mg/kg/day 2.5 mg/kg/day 5 mg/kg/day Day 1 n = 8 Last n = 7 1 n = 7 Last n = 7 1 n = 12 Last n = 9 Parameters Cmax (mcg/mL) 7.3 ± 3.8 12.2 ± 4.9 17.2 ± 7.1 31.4 ± 17.8 57.6 ± 21 83 ± 35.2 AUC0-24 (mcg•hr/mL) 27 ± 14 60 ± 20 65 ± 33 197 ± 183 269 ± 96 555 ± 311 t½(hr) 10.7 ± 6.4 7 ± 2.1 8.1 ± 2.3 6.3 ± 2 6.4 ± 2.1 6.8 ± 2.1 Vss (L/kg) 0.44 ± 0.27 0.14 ± 0.05 0.40 ± 0.37 0.16 ± 0.09 0.16 ± 0.10 0.10 ± 0.07 Cl (mL/hr/kg) 39 ± 22 17 ± 6 51 ± 44 22 ± 15 21 ± 14 11 ± 6 Distribution Based on total amphotericin B concentrations measured within a dosing interval (24 hours) after administration of amphotericin B liposome for injection, the mean half-life was 7 to 10 hours.

However, based on total amphotericin B concentration measured up to 49 days after dosing of amphotericin B liposome for injection, the mean half-life was 100 to 153 hours. The long terminal elimination half-life is probably a slow redistribution from tissues. Steady state concentrations were generally achieved within 4 days of dosing.

Although variable, mean trough concentrations of amphotericin B remained relatively constant with repeated administration of the same dose over the range of 1 mg/kg/day to 5 mg/kg/day, indicating no significant drug accumulation in the serum. Metabolism The metabolic pathways of amphotericin B after administration of amphotericin B liposome for injection are not known.

Excretion The mean clearance at steady state was independent of dose. The excretion of amphotericin B after administration of amphotericin B liposome for injection has not been studied. Pharmacokinetics in Special Populations Renal Impairment The effect of renal impairment on the disposition of amphotericin B after administration of amphotericin B liposome for injection has not been studied.

However, amphotericin B liposome for injection has been successfully administered to patients with preexisting renal impairment (see DESCRIPTION OF CLINICAL STUDIES). Hepatic Impairment The effect of hepatic impairment on the disposition of amphotericin B after administration of amphotericin B liposome for injection is not known.

Pediatric and Elderly Patients The pharmacokinetics of amphotericin B after administration of amphotericin B liposome for injection in pediatric and elderly patients has not been studied; however, amphotericin B liposome for injection has been used in pediatric and elderly patients (see DESCRIPTION OF CLINICAL STUDIES). Gender and Ethnicity The effect of gender or ethnicity on the pharmacokinetics of amphotericin B after administration of amphotericin B liposome for injection is not known.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Amphotericin B (Lipid Complex) 50 mg Vial₱9,975.00–₱10,973.00Reference ₱9,975.00per vialDPRI procurement range
Amphotericin B (Non-Lipid Complex) 50 mg Vial₱800.00–₱3,150.00Reference ₱988.00per vialDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Amphotericin B (Lipid Complex) (as cholesteryl complex, colloidal dispersion); Amphotericin B (Non-Lipid Complex)
PNF listingInj.: 50 mg and 100 mg vial (IV infusion)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Reserve antimicrobial (PNF)
PNF listingInj.: 50 mg lyophilized powder, vial (IV infusion)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Reserve antimicrobial (PNF)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Amphotericin B · Sun Pharmaceutical Industries, Inc. [US FDA-approved label, version 3, April 20, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02aadef1-390b-4270-b56d-33452eb89dde
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .